国际产前外显子组测序表型入选标准的性能:系统综述及基于历史个体参与者数据的比较诊断准确性研究
该研究通过在线调查了解各国产前外显子组测序(pES)的开展与病例选择方式,并在1054例结构异常胎儿的历史队列中比较英格兰、希腊、加拿大(不列颠哥伦比亚和安大略)及西班牙的五套表型入选标准。NHS标准总诊断率为27.8%(69/248),汇总灵敏度49.8%、特异度80.7%、AUC 0.66;不列颠哥伦比亚标准汇总灵敏度70.5%、特异度68.9%、AUC 0.73。现行(2024)基因panel诊断率显著高于原(2020)panel(95.6% vs 87.4%,P=0.017)。
要点
- 调查显示多数国家按胎儿表型及单基因病可能性逐例选择pES,而非依据预设表型标准。
- NHS标准总诊断率27.8%(69/248),汇总灵敏度49.8%、特异度80.7%、AUC 0.66。
- 现行2024基因panel诊断率95.6%(129/135)显著高于2020 panel的87.4%(118/135),P=0.017。
核心结论
- 在调查有回复的国家中,多数按胎儿表型及潜在单基因病的可能性逐例提供pES。
- 现有pES表型入选标准的性能中等。
研究设计与样本
- 在线调查覆盖120个国家,收到63/120个国家的261份回复。
- 在源自已发表系统综述的1054例未选择结构异常胎儿历史队列中测试五套表型入选标准。
- 比较现行(2024)与原始(2020)NHS pES基因panel在未选择队列中的诊断率。
主要发现
- 在可推断的国家中,81.8%(45/55)提供pES;在说明选择方式的国家中,90.3%(28/31)按胎儿表型及单基因病可能性逐例选择。
- NHS标准总诊断率27.8%(69/248),汇总灵敏度49.8%(95%CI 31.7-67.9%)、汇总特异度80.7%(95%CI 59.6-92.2%)、AUC 0.66(95%CI 0.53-0.74)。
- 孤立性长骨短小的诊断率最高,为58.3%(7/12)。
- 满足NHS标准数量增加时,单基因诊断可能性未显著增加。
- 现行(2024)vs原始(2020)NHS基因panel诊断率:129/135(95.6%)vs 118/135(87.4%),P=0.017。
关键数值与推荐
- NHS标准:总诊断率27.8%(69/248),汇总灵敏度49.8%(95%CI 31.7-67.9%),汇总特异度80.7%(95%CI 59.6-92.2%),AUC 0.66(95%CI 0.53-0.74)。
- 不列颠哥伦比亚标准:汇总灵敏度70.5%(95%CI 43.7-88.1%),汇总特异度68.9%(95%CI 37.5-89.1%),AUC 0.73(95%CI 0.58-0.79)。
- 现行(2024)vs原始(2020)NHS基因panel诊断率:129/135(95.6%)vs 118/135(87.4%),P=0.017。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate: (i) the performance of the National Health Service (NHS) phenotypic eligibility criteria for prenatal exome sequencing (pES); (ii) the diagnostic yield of individual NHS criteria; (iii) the diagnostic yield when one or multiple NHS criteria were met; and (iv) the performance of the NHS criteria compared with that of phenotypic eligibility criteria used in other countries/regions. METHODS: An online survey was circulated to healthcare professionals in 120 countries to gather information on whether pES is offered in their country and how case selection is performed. Five predefined sets of phenotypic eligibility criteria from England, Greece, Canada (British Columbia and Ontario) and Spain were tested on a virtual historical cohort of 1054 'unselected' structurally abnormal fetuses undergoing pES, derived from a published systematic review. The performance of the current and previous gene panels used in the NHS pES service was assessed in the unselected cohort. The sensitivity and specificity with 95% CI for each set of criteria in relation to diagnostic yield for pathogenic and likely pathogenic variants were calculated, along with the area under the summary receiver-operating-characteristics curve (AUC). RESULTS: The electronic survey received 261 responses from 63/120 countries. Where deducible, 81.8% (45/55) of the countries surveyed offered pES. Where stated, most (90.3% (28/31)) cases were selected for pES on a case-by-case basis, according to fetal phenotype and the likelihood of an association with a monogenic condition, rather than on the basis of predetermined phenotypic criteria. The total diagnostic yield of the NHS criteria when applied to all relevant cases for pES was 27.8% (69/248), with pooled sensitivity, pooled specificity and AUC of 49.8% (95% CI, 31.7-67.9%), 80.7% (95% CI, 59.6-92.2%) and 0.66 (95% CI, 0.53-0.74), respectively. The diagnostic yield was highest for isolated short long bones (58.3% (7/12)). The likelihood of a monogenic diagnosis did not increase significantly as the number of NHS criteria met increased. There was a significant increase in the diagnostic yield of the current (2024) vs original (2020) gene panel adopted by the NHS (129/135 (95.6%) vs 118/135 (87.4%); P = 0.017). The four other sets of phenotypic criteria used in other countries/regions performed moderately well, with the best performance seen for the British Columbia criteria, which had a pooled sensitivity of 70.5% (95% CI, 43.7-88.1%), pooled specificity of 68.9% (95% CI, 37.5-89.1%) and AUC of 0.73 (95% CI, 0.58-0.79). CONCLUSIONS: In the majority of countries for which there was a survey response, pES was offered on a case-by-case basis, according to fetal phenotype and the likelihood of an underlying monogenic condition. Existing phenotypic eligibility criteria for pES performed modestly. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Reilly K, Rolnik DL, Allen S, et al. Performance of international phenotypic criteria for prenatal exome sequencing: systematic review and comparative diagnostic accuracy study using historical individual participant data. Ultrasound Obstet Gynecol. 2025. PMID: 40627867. doi:10.1002/uog.29290
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。